Page last updated: 2024-12-10

9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo(1,2-alpha)benzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4641302
MeSH IDM0592218

Synonyms (9)

Synonym
STK870445
2-(4-fluorophenyl)-9-[2-(morpholin-4-yl)ethyl]-9h-imidazo[1,2-a]benzimidazole
AKOS001887473
4-[2-[2-(4-fluorophenyl)imidazo[1,2-a]benzimidazol-4-yl]ethyl]morpholine
CCG-145744
AB01284802-01
HMS3448P17
NCGC00289676-01
9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo(1,2-alpha)benzimidazole

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of a new imidazobenzimidazole derivative, compound RU-1205, were studied after peroral administration to rabbits at a dose of 50 mg/kg as a parent substance and in coated tablet dosage form."( [Pharmacokinetic and analgesic properties of tabletized dosage form of RU-1205-new imidazobenzimidazole derivative with kappa agonist activity].
Anisimova, VA; Grechko, OIu; Rashchenko, AI; Shtareva, DM; Smirnova, LA; Spasov, AA, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" It is established that RU-1205 substance has high bioavailability (44."( [The absolute bioavailability of benzimidazole derivative RU-1205 in rats].
Anisimova, VA; Kuznetsov, KA; Rashchenko, AI; Smirnova, LA; Spasov, AA, 2014
)
0.4
" It was found that RU-1205 tablets are characterized by high values of the relative bioavailability (105."( [Pharmacokinetic and analgesic properties of tabletized dosage form of RU-1205-new imidazobenzimidazole derivative with kappa agonist activity].
Anisimova, VA; Grechko, OIu; Rashchenko, AI; Shtareva, DM; Smirnova, LA; Spasov, AA, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
"The pharmacokinetic properties of a new imidazobenzimidazole derivative, compound RU-1205, were studied after peroral administration to rabbits at a dose of 50 mg/kg as a parent substance and in coated tablet dosage form."( [Pharmacokinetic and analgesic properties of tabletized dosage form of RU-1205-new imidazobenzimidazole derivative with kappa agonist activity].
Anisimova, VA; Grechko, OIu; Rashchenko, AI; Shtareva, DM; Smirnova, LA; Spasov, AA, 2014
)
0.4
"Pharmacokinetic properties of imidazobenzimidazole derivative compound RU-1205 were investigated after subcutaneous administration to rabbits as a substance and a dosage form (lyophilisates for injection) at a dose of 25 mg/kg."( [Pharmacokinetic and analgesic properties of the injectable dosage form of a new imidazobenzimidazole derivative RU-1205 with kappa agonist activity].
Anisimova, VA; Grechko, OU; Raschenko, AI; Shtareva, DM; Smirnova, LA; Spasov, AA,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]